Back to search

Article

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS

2011-11-18

Abstract excerpt

Abstract Abstract 461 Aberrant DNA methylation is a hallmark of myelodysplastic syndromes (MDS), MDS/myeloproliferative neoplasms (MDS/MPN) and secondary acute myeloid leukemia (sAML). It provides a rationale for treating these malignancies with hypomethylating agents like 5-azacitidine (AZA) and decitabine (DAC). However, treatment outcomes remain limited and heavily weighed on morphologic/cytogenetic results. Th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7bf4557d-81c4-5379-bbe0-396dbceae396
DOI
10.1182/blood.v118.21.461.461
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDSDOI 10.1182/blood.v118.21.461.461
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.Semantic proximity
Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidineSemantic proximity
Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromesSemantic proximity
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity
Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted TherapySemantic proximity
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.Semantic proximity
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity
Select a neighboring publication to make it the new centre.